DelMar Pharmaceuticals, Inc. logo

DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is a clinical and commercial stage drug development company with a focus on the treatment of cancer. DelMar Pharmaceuticals (OTCQX: DMPI) is a biotech company, developing therapies against neurological cancers. Its lead molecule VAL-083 is a chemotherapy drug in ph I/II clinical trials for the treatment of refractory glioblastoma multiforme.

In 2010, DelMar acquired worldwide development rights, patents and the prototype drug product related to VAL-083 from Valent Technologies LLC, California.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”DMPI” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.delmarpharma.com
Founded2010
Disease Focus
Development Stage
STOCK CODENASDAQ: DMPI
Address
Suite 720 - 999 West Broadway, British Columbia V5Z 1K5
Vancouver
Canada
Email
Contact Number
+1 604-629-5989

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/delmar-pharmaceuticals” connections=”true” suffix=””]

In 2012, DelMar entered into an agreement with Guangxi Wuzhou Pharmaceutical (a subsidiary of Guangxi Wuzhou Zhongheng Group) to manufacture and sell VAL-083 in China.